Oral Idarubicin in Pretreated Pediatric Acute Leukemia
Anthracyclines are among the most useful drugs in the treatment of both lymphoblastic (ALL) and nonlymphoblastic (ANLL) acute leukemias of childhood. However, the benefit of the most commonly used anthracyclines daunorubicin and doxorubicin is limited by their cardiotoxicity  and by resistance against these compounds. The daunorubicin analog idarubicin (4-demethoxydaunorubicin) might be less cardiotoxic and has shown greater antileukemic efficacy in some preclinical and clinical trials . In addition, the chemical structure of idarubicin leads to appreciable resorption of active drug after oral application [3, 4], allowing therapy in an outpatient setting. We therefore conducted an open, multicenter trial assessing the toxicity and efficacy of oral idarubicin in refractory acute leukemia in children.
KeywordsMaximum Tolerate Dose Acute Leukemia Antileukemic Activity Oral Idarubicin Refractory Acute Leukemia
Unable to display preview. Download preview PDF.
- 1.Von Hoff DD, Rosencweig M, Piccart M (1980) The cardiotoxicity of anticancer agents. Semin Oncol 9: 23Google Scholar
- 2.Carella AM, Berman E, Maraone M, Ganzi-na F (1990) Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Haematologica (Pavia) 75: 1–11Google Scholar
- 5.Wiernik P (ed) (1989) Idarubicin: a new presence in leukemias. Semin Oncol 16 [Suppl 2]: 1–36Google Scholar
- 8.Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, Clarkson BD, Young CW (1985) Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res 45: 1408–1412PubMedGoogle Scholar
- 9.Carella AM, Santini G, Martinengo M, et al. (1985) 4-Demethoxydaunorubicin in refractory or relapsed acute leukemias. A pilot study. Cancer 55 1452–1454Google Scholar
- 10.Harrousseau JL, Hurteloup P, Reiffers J, et al. (1987) Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia. Cancer Treat Rep 71: 991–995Google Scholar
- 13.Harris R, Feig S, Baum E, Holcenberg J, Pendergrass T, Bleyer A, Holt C, Krailo M, Hammond D (1988) Idarubicin ( IDR) vs daunomycin for reinduction of relapsed childhood ALL - a CCSG study. Proc Am Soc Clin Oncol 7: 189Google Scholar
- 14.Tan C, Bacha D, Hancock C (1984) New anthracyclines in childhood cancer. 14th International Congress of Chemotherapy, (abstr No 104)Google Scholar
- 15.Pui CH, de Graaf SS, Dow LW, Rodman JH, Evans WE, Alpert BS, Murphy SB (1988) Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. Cancer Res 48: 5348–5352Google Scholar
- 16.Lowenthal RM (1987) A possible special role for oral idarubicin in the treatment of leukemia following myelodysplastic syndrome. In: Mandelli F, Polli E, Clarkson B (eds) Proceedings of the session in idarubicin in the treatment of acute leukemia. 4th International Symposium on Therapy of Acute Leukemia. Excerpta Medica, Amsterdam, pp 50–55Google Scholar